Oblimersen: Difference between revisions

Latest revision as of 03:51, 13 February 2025

Overview[edit]

Oblimersen is an antisense oligonucleotide that has been studied for its potential use in cancer therapy. It is designed to target the Bcl-2 protein, which is known to inhibit apoptosis and is often overexpressed in various types of cancer. By reducing the levels of Bcl-2, oblimersen aims to promote apoptosis in cancer cells, thereby enhancing the effectiveness of other anticancer treatments.

Mechanism of Action[edit]

Oblimersen works by binding to the mRNA of the Bcl-2 protein, leading to its degradation and preventing the translation of the Bcl-2 protein. This process is known as antisense therapy. By decreasing the levels of Bcl-2, oblimersen can help to restore the apoptotic pathways in cancer cells, making them more susceptible to chemotherapy and radiation therapy.

Clinical Applications[edit]

Oblimersen has been investigated in clinical trials for several types of cancer, including chronic lymphocytic leukemia (CLL), melanoma, and non-Hodgkin lymphoma. In these studies, oblimersen was often used in combination with other chemotherapeutic agents to assess its ability to enhance treatment efficacy.

Development and Challenges[edit]

The development of oblimersen has faced several challenges, including issues related to its delivery and stability in the body. Antisense oligonucleotides like oblimersen can be rapidly degraded by nucleases, and their delivery to target cells can be inefficient. Researchers have explored various strategies to improve the pharmacokinetics and delivery of oblimersen, such as chemical modifications and the use of delivery vehicles.

Future Directions[edit]

Research on oblimersen and other antisense oligonucleotides continues, with a focus on improving their stability, delivery, and efficacy. Advances in nanotechnology and drug delivery systems may provide new opportunities to enhance the therapeutic potential of oblimersen in cancer treatment.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-'''Oblimersen''' (also known as '''Genasense''', '''G3139''', or '''BCL-2 antisense oligonucleotide''') is a synthetic [[antisense oligonucleotide]] that has been studied for its potential use in the treatment of various types of [[cancer]]. It was developed by [[Genta Incorporated]], a biopharmaceutical company specializing in the development of innovative drugs for the treatment of cancer and other serious diseases.
+{{DISPLAYTITLE:Oblimersen}}
+== Overview ==
+'''Oblimersen''' is an antisense oligonucleotide that has been studied for its potential use in cancer therapy. It is designed to target the [[Bcl-2]] protein, which is known to inhibit [[apoptosis]] and is often overexpressed in various types of [[cancer]]. By reducing the levels of Bcl-2, oblimersen aims to promote apoptosis in cancer cells, thereby enhancing the effectiveness of other anticancer treatments.
 == Mechanism of Action ==
+Oblimersen works by binding to the mRNA of the Bcl-2 protein, leading to its degradation and preventing the translation of the Bcl-2 protein. This process is known as [[antisense therapy]]. By decreasing the levels of Bcl-2, oblimersen can help to restore the apoptotic pathways in cancer cells, making them more susceptible to [[chemotherapy]] and [[radiation therapy]].
-Oblimersen works by targeting and inhibiting the [[BCL-2]] gene, which is often overexpressed in cancer cells. The BCL-2 gene is responsible for producing a protein that inhibits cell death, allowing cancer cells to survive and proliferate. By inhibiting the BCL-2 gene, oblimersen may help to induce [[apoptosis]], or programmed cell death, in cancer cells.
+== Clinical Applications ==
+Oblimersen has been investigated in clinical trials for several types of cancer, including [[chronic lymphocytic leukemia]] (CLL), [[melanoma]], and [[non-Hodgkin lymphoma]]. In these studies, oblimersen was often used in combination with other chemotherapeutic agents to assess its ability to enhance treatment efficacy.
-== Clinical Trials ==
-Several [[clinical trials]] have been conducted to evaluate the safety and efficacy of oblimersen in various types of cancer, including [[melanoma]], [[chronic lymphocytic leukemia]] (CLL), and [[multiple myeloma]]. While some trials have shown promising results, others have not met their primary endpoints, and the drug has not yet been approved by the [[Food and Drug Administration]] (FDA) for use in the United States.
-== Potential Side Effects ==
+== Development and Challenges ==
+The development of oblimersen has faced several challenges, including issues related to its delivery and stability in the body. Antisense oligonucleotides like oblimersen can be rapidly degraded by nucleases, and their delivery to target cells can be inefficient. Researchers have explored various strategies to improve the pharmacokinetics and delivery of oblimersen, such as chemical modifications and the use of delivery vehicles.
-Like all drugs, oblimersen may cause side effects. In clinical trials, the most common side effects reported were [[fatigue]], [[nausea]], and [[fever]]. More serious side effects, such as [[thrombocytopenia]] (low platelet count) and [[neutropenia]] (low white blood cell count), were also reported.
+== Future Directions ==
+Research on oblimersen and other antisense oligonucleotides continues, with a focus on improving their stability, delivery, and efficacy. Advances in [[nanotechnology]] and [[drug delivery systems]] may provide new opportunities to enhance the therapeutic potential of oblimersen in cancer treatment.
-== Future Research ==
+== Related Pages ==
+* [[Antisense therapy]]
+* [[Bcl-2]]
+* [[Apoptosis]]
+* [[Cancer treatment]]
-Despite the mixed results of clinical trials, research into the potential uses of oblimersen continues. Scientists are particularly interested in exploring its potential use in combination with other cancer treatments, such as [[chemotherapy]] and [[immunotherapy]].
+[[File:Oblimersen.svg|thumb|right|Diagram of Oblimersen structure]]
-[[Category:Antisense oligonucleotides]]
+[[Category:Antisense therapy]]
 [[Category:Cancer treatments]]
-[[Category:Experimental drugs]]
-{{Medicine-stub}}